Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer

Bor-Ching Sheu, Rong-Hwa Lin, Huang-Chun Lien, Hong-Nerng Ho, Su-Ming Hsu and Su-Cheng Huang

*J Immunol* 2001; 167:2972-2978; doi: 10.4049/jimmunol.167.5.2972

http://www.jimmunol.org/content/167/5/2972

References This article cites 46 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/167/5/2972.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer

Bor-Ching Sheu,* Rong-Hwa Lin,‡ Huang-Chun Lien,† Hong-Nerng Ho,,** Su-Ming Hsu ‡, and Su-Cheng Huang2*

Cytotoxic T lymphocytes (Tc) play a central role in cellular immunity against cancers. The cytotoxic potential of freshly isolated tumor-infiltrating lymphocytes (TILs) is usually not expressed. This suggests the possible existence of as yet unspecified and perhaps complex immunosuppressive factors or cytokines that affect the anti-tumor capacity of these TILs in the tumor milieu. In the present study, we demonstrated for the first time that TILs derived from human cervical cancer tissue consist mainly of Th2/Tc2 phenotypes. In vitro kinetic assays further revealed that cancer cells could direct the tumor-encountered T cells toward the Th2/Tc2 polarity. Cancer cells promote the production of IL-4 and down-regulate the production of IFN-γ in cancer-encountered T cells. The regulatory effects of cervical cancer cells are mediated mainly by IL-10, and TGF-β plays only a synergistic role. The cancer-derived effects can be reversed by neutralizing anti-IL-10 and anti-TGF-β Abs. IL-10 and TGF-β are present in cancer tissue and weakly expressed in precancerous tissue, but not in normal cervical epithelial cells. Our study strongly suggests important regulatory roles of IL-10 and TGF-β in cancer-mediated immunosuppression. The Journal of Immunology, 2001, 167: 2972–2978.

Since the discovery of polarized cytokine patterns among CD4+ T cells, studies have concentrated on the physiologic significance of the polarized T cells in immunity (1–6). The polarized T cell phenotype was originally based on the analyses of mouse T cell clones cultured in vitro, with dichotomous and cross- regulatory patterns of cytokine produced by two functionally distinct subsets, Th1 and Th2 cells (2–6). Recently, it has been demonstrated that naive CD8+ T cells are able to differentiate into a T cytotoxic-1 (Tc1) subset that produces IL-2 and IFN-γ, or a Tc2 subset that produces IL-4, IL-5, and IL-10 (5–9). In human T cell clones, Th1/Tc1 cells preferentially develop during infections with intracellular bacteria and enhance phagocyte-mediated immunity, whereas Th2/Tc2 cells predominate during metazoan parasitic infestations and in atopic diseases (4–6). Although both types of CD8+ T cell subsets are thought to possess a cytolytic function in vitro, there is substantial evidence indicating that CD8+ T cells secreting type 1 and type 2 cytokines in vivo might have great relevance to immune responses (10–13). In a recent study of TCR-transgenic mice, Tc2 has been demonstrated to be less protective than Tc1 against pulmonary influenza virus infection (13). Because Tc cells play a central role in cellular immunity against cancers, alterations of Tc1/Tc2 subsets in the tumor microenvironment may change host anti-tumor immune responses (8–12).

In human cervical cancer (CC) as well as in other cancers, depressed anti-tumor immunity of Tc cells has been observed (14–16). The cytotoxic potential of freshly isolated tumor-infiltrating lymphocytes (TILs) is usually not expressed (16–18). This suggests the possible existence of as yet undefined mechanisms that affect the anti-tumor capacity of these TILs in the tumor milieu. Previously, we have demonstrated that cancer cells may alter the functional composition of anti-tumor effector cells (e.g., CD3+CD25+ T cells) within the tumor milieu (19, 20). We have further illustrated that a decreased proportion of CD4+ T cells is responsible for the reversed CD4/CD8 ratio of TILs in human CC (20). Because the tumor-reactive CD4+ T cells can be activated through the MHC class II pathway to produce lymphokines and amplify the cytotoxic activity of CD8+ T cells (21, 22), a decreased proportion of CD4+ T cells with a reversed CD4/CD8 ratio in vivo may result from functional alterations of T cells within the tumor microenvironment.

In this study, we examined the functional characteristics of TILs by investigating their cytokine expression (23, 24). We used an in vitro mixed autologous lymphocyte and tumor-cell coculture (MLTC) model to evaluate the kinetic expression of cytokines by cancer-encountered T cells (25). Our results demonstrate for the first time that activated T cells in the human cancer milieu predominantly express a Th2/Tc2 phenotype, and that cancer cells can directly drive the tumor-encountered T cells toward Th2/Tc2 polarity through an IL-10- and TGF-β-mediated pathway.

Materials and Methods

Immunocyte isolation and activation for cytokine production Patients with stage Ib CC admitted for operation were prospectively enrolled in this study. A complete history was obtained for each patient. Informed consent was obtained for collecting the materials in this study.

Copyright © 2001 by The American Association of Immunologists

0222-1767/01/$02.00

Received for publication March 16, 2001. Accepted for publication June 18, 2001.
After radical hysterectomy, the surgical specimens were carefully examined by experienced pathologists. Tissue specimens were excised aseptically immediately after operation from at least four different tumor sites and two sites from normal cervical epithelium of the same tumor patients. Fragments of tissue were washed with PBS for removal of contaminated blood. CC cells, cervical epithelial cells, and TILs were isolated according to methods described previously (19, 20, 25). For matched comparison, venous blood of each patient was obtained before operation and transferred to test tubes containing heparin. PBMCs were isolated by Ficoll-Hypaque (1.077 density) and resuspended at a concentration of 1 × 10^6 cells/ml in RPMI 1640 medium. The recovered cells were checked and counted for viability with the trypan blue staining method. Purified TILs and PBMCs (1 × 10^6 cells/ml) were activated in medium containing PMA at 25 ng/ml, ionomycin at 1 μg/ml, and brefeldin A at 10 μg/ml. The activated cells were incubated in a 37°C, 5% CO2 humidified incubator for 18 h. The activation status was monitored by surface staining of CD69.

**Surface and intracellular staining**

Mononuclear Abs labeled with FITC, PE, and PerCP were used for triple-color flow cytometry as previously described (19, 20, 25). For surface Ag staining, 20 μl anti-CD4-FITC, anti-CD8-FITC, and/or anti-CD3-PerCP (BD Immunocytometry Systems, San Jose, CA) were used for every set of 1 × 10^6 activated T cells. After incubation for 30 min, cells were washed twice with 1 ml lysing buffer, and fixed with 1 ml fixation buffer containing 1% paraformaldehyde. Cells were washed twice with 500 μl permeabilization buffer containing 0.5% saponin, and stained with 20 μl fluorescence-conjugated anti-cytokine mAbs for an additional 30 min at room temperature. Anti-IFN-γ-PE, anti-IL-5-PE (BD PharMingen; San Diego, CA), and anti-IL-4-FTC plus anti-IFN-γ-PE (BD Immunocytometry Systems) were used for intracellular staining. Anti-mouse cytosol-IgG1-FITC + cytosol-IgG2a-PE was used as negative control. Triple-color flow cytometry was performed on a FACSCalibur (BD Biosciences, Mountain View, CA). Data were acquired with CellQuest software (BD Biosciences) by the use of forward-scatter/side-scatter thresholds with 10,000 gated events. We used Leukogate to measure the proportion of lymphocytes in the sample being studied. In triple-color assays with cytokine expression, data were further gated on FL3^+ cells with a CD3 trigger for evaluation of T cell subsets.

**Purification of CD8^+ cytotoxic T lymphocytes**

CD8^+ T cells were isolated from TILs by use of an indirect magnetic labeling system with a MACS (Miltenyi Biotec, Gladbach, Germany). The cells were suspended in PBS medium containing 20 μl of Hepton-Ab Cocktail (containing CD4, CD11b, CD16, CD19, CD36, and CD56 Abs; Miltenyi Biotec) and incubated in a cold room (6-12°C) for 10 min. After repeated washing, 20 μl of MACS anti-hepentransmicrobeads per 10^7 total cells was added. The suspension was further incubated for 15 min at 6-12°C, then washed carefully by the addition of 10-20X the labeling volume of the washing buffer. The magnetically labeled cells were passed through a MACS separator in a magnetic field. The column was rinsed with an adequate volume of buffer and repeatedly eluted. The effluent was collected as negative fraction, representing the enriched CD8^+ T cell subset.

**RT-PCR analysis of mRNA expression**

We measured the cytokine mRNA expression in purified CD8^+ T cells derived from TILs and PBMCs, CC cells, and normal cervical epithelial cells by RT-PCR. The mRNAs of cytokines involved in the functional T cell development were examined. Total cellular RNA was extracted and reverse-transcribed (0.1–0.5 μg RNA) in the presence of IL-4, IL-10, IL-12, IFN-γ, TNF-α, and TGF-β oligonucleotide primers (CLONTECH Laboratories, Palo Alto, CA). Human β-actin primers were used as positive controls. The PCR was performed in a DNA thermal cycler (GeneAmp DNA thermal cycler 480; PerkinElmer, Norwalk, CT) for 36 cycles of denaturation at 94°C for 40 s, annealing at 55°C for 40 s, and extension at 72°C for 40 s. For matched comparison, a constant number (5 × 10^5) of PBMCs was cultured as the T-only group. Mouse anti-human IgG1 and rat anti-human IgG (10 μg/ml) were used as isotype Ab controls. The supernatant of the coculture was collected at the same intervals and checked for the presence of IL-4 and IFN-γ.

**Statistical analysis of data**

Data analysis was performed with a statistical analysis system (R.6.12; SAS Institute, Cary, NC). The Wilcoxon signed-ranks test was used for comparison of the median expression ratio of cytokine expression in CD3^+, CD3^+CD4^+-, and CD3^+CD8^+ T cell subsets between TILs and PBMCs. Kinetic data of MLTC and MLNC were analyzed by a generalized estimation equation for correlated data of repeated measurements and were expressed as mean ± SD. Statistical significance was defined by a p value <0.05.

**Results**

**Determination of the subtypes of Tc cells in TILs**

Histologic examination of the specimens revealed that all CC cases were squamous cell carcinomas. The viability of immunocytes was ~90–95% at the completion of the isolation procedure in all cases.
In triple-color flow cytometric assays with dual-cytokine intracellular staining of eight CC cases, gated CD3+ T cells (Fig. 1, a and b) derived from TILs expressed mainly IL-4, but not IFN-γ (Fig. 1c). In contrast, prominent expression of IFN-γ, but not IL-4, was observed in activated CD3+ PBMCs (Fig. 1d). Subsequent staining of dual-surface phenotyping in combination with cytokine intracellular staining showed that the expression of these cytokines was restricted to particular subsets of T cells (Fig. 1, e–h). Prominent expression of IL-5 with low expression of IFN-γ was demonstrated in both gated CD3+CD4+ (data not shown) and CD3+CD8+ TIL subsets (Fig. 1, e and f) derived from CC tissue. Contrarily, prominent expression of IFN-γ with low expression of IL-5 was detected in both activated CD3+CD4+ (data not shown) and CD3+CD8+ PBMCs (Fig. 1, g and h). Flow cytometric analyses further defined the ratios of intracellular cytokine expression in individual T cell subsets (Fig. 2, a and b). The median expression ratio of IL-5 on CD3+CD4+ cells was significantly higher in TILs than in PBMCs (60.71 vs 0.25%, n = 8, p < 0.01). A similar finding was observed with CD3+CD8+ cells (66.73 vs 0.28%, n = 8, p < 0.01), which signified the predominant Th2/Tc2 patterns of cytokine expression in TILs.

We also analyzed the IL-4 and IFN-γ mRNA expression in CD8+ T cells isolated from TILs and activated PBMCs (Fig. 2c). Similar to the result obtained with intracellular staining, we observed the abundant expression of IL-4 mRNA, but low expression of IFN-γ mRNA, in CD8+ TILs. The PBMC-derived CD8+ T

![FIGURE 1](http://www.jimmunol.org/Downloaded) Representative dot-plots of dual-intracellular cytokine staining-gated CD3+ T cells in TILs and PBMCs. a, Data were acquired with forward scatter (FSC)/side scatter (SSC) thresholds with 10,000 gated events. We used leukogate (R1) to measure the proportion of lymphocytes in the sample being studied. b, In triple-color assays with cytokine expression, data were further gated on FL3+ cells with a CD3 trigger (R2) for evaluation of the CD3+ T cell subsets. c, Prominent expression of IL-4 in gated CD3+ TILs derived from CC tissue. d, Prominent expression of IFN-γ in gated CD3+ PBMCs. e, Low expression of IFN-γ in gated CD3+CD8+ TILs derived from CC tissue. f, Prominent expression of IL-5 in gated CD3+CD8+ TILs derived from CC tissue. g, Prominent expression of IFN-γ in gated CD3+CD8+ PBMCs. h, Low expression of IL-5 in gated CD3+CD8+ PBMCs.

![FIGURE 2](http://www.jimmunol.org/Downloaded) Polarized cytokine production in TILs and PBMCs after PMA and ionomycin activation. The data are representative of median expression ratios (%) of eight independent assays. a, IL-4 was predominantly expressed in the CD3+ TILs, with IFN-γ predominantly expressed in the corresponding CD3+ PBMCs. b, IL-5 was predominantly expressed in both the CD3+CD4+ and CD3+CD8+ TILs, with IFN-γ predominantly expressed in the corresponding CD3+CD4+ and CD3+CD8+ PBMCs. c, Analysis of IL-4 and IFN-γ mRNA expression in purified CD8+ T cells. The CD8+ T cells were isolated from TILs and PBMCs. For each sample, constant amounts of reverse-transcribed RNA were amplified. Human β-actin mRNA (838 bp) was used as positive control. Representative data show that prominent IL-4 mRNA (344 bp) was expressed in CD8+ TILs, but only weakly expressed in activated CD8+ T cells derived from PBMCs. IFN-γ mRNA (427 bp) was abundantly expressed in PBMC-derived CD8+ T cells, but weakly in TIL-derived CD8+ T cells (lanes 1, 3, and 5, TILs; lanes 2, 4, and 6, stimulated PBMCs; M, markers).
cells prominently expressed IFN-γ mRNA and low expression of IL-4 mRNA. The results emphasized that tumor-encountered T cells in the cancer milieu have a predominant Th2/Tc2 phenotype of mRNA expression and cytokine production.

**Determination of the effects of cancer cells on TILs**

It is possible that CC cells can direct the differentiation of activated T cells toward Th2/Tc2 polarity. To clarify this possibility, we used a previously established in vitro cancer-host interaction model and analyzed the cytokine production of IL-4 and IFN-γ in the supernatants of MLTC and MLNC (25). In six sets of repeated experiments, the mean concentration of IFN-γ in MLNC supernatants was 201.2 ± 16.4 pg/ml and increased >1- and 2-fold by days 3 and 5, respectively. However, the mean concentration of IFN-γ in the supernatants of MLTC was significantly lower than that of MLNC in day 5 cocultures (n = 6, p < 0.01) (Fig. 3a). The mean concentration of IL-4 in MLNC supernatants was 64.1 ± 6.6 pg/ml and increased by <1-fold by days 3 and 5. However, the mean concentration of IL-4 in the supernatants of MLTC was significantly higher than that in MLNC in day 3 and day 5 cocultures (increased >3- and 4-fold, respectively) (n = 6, p < 0.001) (Fig. 3b). It became evident that CC cells could promote the production of IL-4 and possibly abrogate the production of IFN-γ in cancer-encountered T cells.

**Determination of immunosuppressive mediators expressed by cancer cells**

To examine the possible cancer-derived immunosuppressive factors or cytokines that regulate the functional development or polarization of cancer-encountered T cells, we further compared the mRNA expression of immunoregulatory cytokines, including IL-4, IL-10, IL-12, IFN-γ, TNF-α, and TGF-β, in 30 samples of CC cells. IL-4, IL-12, IFN-γ, and TNF-α mRNAs were not detected in either cancer or epithelial cells. However, TGF-β and IL-10 mRNAs were highly expressed in the CC cells, but not in the normal cervical epithelial cells (Fig. 3c). We then studied the existence of TGF-β and IL-10 in CC by immunohistochemical staining of CC tissues from 47 patients. TGF-β and IL-10 were abundantly expressed in most, if not all cancer cells, but were not or only very weakly expressed in normal cervical epithelial or stromal cells (Fig. 4, a and b). The expression of TGF-β and IL-10 became obvious in transitional sections from normal cervical epithelium to carcinoma-in-situ and invasive cancer areas (Fig. 4, c and d). Unlike the expression of TGF-β and IL-10 in cancer cells, the expression of other types of immunoregulatory cytokines was not detected.

**Determination of the function of IL-10 and TGF-β in T cell polarity**

To characterize the possible role of IL-10 and TGF-β in the polarity of cancer-encountered T cells further, we directly incubated anti-IL-10 and anti-TGF-β Abs in the autologous MLTC. Using the kinetic experiments on MLTC described above, we determined whether specific blocking Abs could reverse or limit the cancer-induced effects. PBMCs were fully activated as matched controls (activated T-cells-only group). In six sets of matched experiments after 5 days of coculture, the mean concentration of IFN-γ in the supernatants of MLTC was significantly lower than that in the T-cells-only group (287.05 ± 17.12 vs 811.40 ± 30.96 pg/ml, n = 6, p < 0.01) (Fig. 5a). The mean concentration of IL-4 in the MLTC group was ~3-fold that in the activated T-cells-only group (347.06 ± 13.61 vs 103.39 ± 18.34 pg/ml, n = 6, p < 0.01) (Fig. 5b).

By addition of anti-IL-10 Ab, an increase in the mean concentration IFN-γ in the supernatants of MLTC was observed in day 3 and day 5 cocultures (Fig. 5a). The mean concentration of IL-4 in the supernatants of MLTC was synchronously reduced on day 3 and day 5 cocultures (48 and 57% decrease, respectively) (Fig. 5b). The effect of anti-TGF-β Ab on cancer-induced IL-4 production was not as obvious as that of the anti-IL-10 Ab, with only 19 and 25% decreases in day 3 and day 5 cocultures, respectively. However, adding both anti-IL-10 and anti-TGF-β Abs in MLTC achieved a maximal reduction of IL-4 in the supernatants, being 65 and 70% reductions in day 3 and day 5 cocultures, which were close to the mean concentrations of IL-4 in the supernatants of the T-cells-only group (Fig. 5b). The effects of anti-IL-10 and anti-TGF-β Abs were also observed in the patterns of IFN-γ in the supernatants of MLTC (Fig. 5a). The isotype controls did not alter the production of IL-4 or IFN-γ in the MLTC (data not shown). Our data illustrated that cancer cells promote the production of IL-4 and abrogate the production of IFN-γ in cancer-encountered CC cells; M, markers.

**FIGURE 3.** CC cells can drive activated T cells toward the Th2/Tc2 polarity. The levels of IL-4 and IFN-γ in the supernatants of MLTC (○) and MLNC (□) were analyzed by ELISA. a, The mean concentration of IFN-γ in the supernatants of MLTC was similar to that in MLNC in day 3, and lower than that of MLNC in day 5 cocultures (p < 0.01). b, The mean concentration of IL-4 in the supernatants of MLTC was significantly higher than that in MLNC in day 3 and day 5 cocultures (p < 0.001). Data from six independent experiments of cocultures in triplicate are presented as mean ± SD. c, Analysis of TGF-β and IL-10 mRNA expression in normal cervical epithelial cells and CC cells. Human β-actin mRNA (838 bp) was analyzed as positive control. Representative data show that the TGF-β mRNA (161 bp) and IL-10 mRNA (328 bp) were highly expressed in CC cells, but not in epithelial cells (lanes 1, 3, and 5, normal epithelial cells; lanes 2, 4, and 6, CC cells; M, markers).
T cells. These cancer-derived effects can be reversed by anti-IL-10 and anti-TGF-β Abs.

Compatible cancer-derived effects and recombinant IL-10/TGF-β on T cell polarity

To clarify the possible synergistic effect of cancer-derived IL-10 and TGF-β on the polarity of T cells, we further incubated activated T cells with recombinant IL-10 and TGF-β in addition to the established autologous MLTC. Using the kinetic experiments on MLTC and the intracellular staining technique described above, we directly determined the cancer-derived effects on cancer-encountered T cells. In eight sets of matched experiments after 3 days of coculture, the median expression ratio of IL-4 was significantly higher in the MLTC (T+C group) than in the activated T-cells-only group (77.28 vs 0.31%, n = 8, p < 0.01). The median expression ratio of IL-4 in T cells treated with recombinant IL-10 and TGF-β was consistent with that in MLTC (72.53 vs 77.28%). Adding both anti-IL-10 and anti-TGF-β Abs in MLTC significantly reduced the expression of IL-4 in CD3⁺ T cells (5.8 vs 77.28%, n = 8, p < 0.01). Similar results were seen in the measurements of IL-4 and IFN-γ of the coculture supernatants. The mean concentration of IL-4 in supernatants of the MLTC group was similar to that of culture of activated T cells in recombinant IL-10 and TGF-β (202.78 ± 74.51 and 199.29 ± 79.77 pg/ml, respectively). Anti-IL-10 and anti-TGF-β Abs in MLTC decreased the median expression ratio of IFN-γ in T cells (5.8 vs 202.78%, n = 8, p < 0.01). The median expression ratio of IFN-γ in MLTC was lower than that in the T-cells-only group (0.46 vs 87.57%, n = 8, p < 0.01). The median expression ratio of IL-4 in T cells treated with recombinant IL-10 and TGF-β was consistent with that in MLTC (72.53 vs 77.28%). Adding both anti-IL-10 and anti-TGF-β Abs in MLTC significantly reduced the expression of IL-4 in CD3⁺ T cells (5.8 vs 77.28%, n = 8, p < 0.01). Similar results were seen in the measurements of IL-4 and IFN-γ of the coculture supernatants. The mean concentration of IL-4 in supernatants of the MLTC group was similar to that of culture of activated T cells in recombinant IL-10 and TGF-β (202.78 ± 74.51 and 199.29 ± 79.77 pg/ml, respectively). Anti-IL-10 and anti-TGF-β Abs in MLTC decreased the mean concentration of IL-4 to the levels of the T-cells-only group, being 56.97 ± 11.94 and 58.49 ± 8.78 pg/ml, respectively. It became evident that human cancer cells have well-matched effects as that of recombinant IL-10 and TGF-β on driving the polarity of cancer-encountered T cells. Importantly, adding anti-IL-10 and anti-TGF-β Abs can reverse the cancer-derived effects.

Discussion

Several lines of evidence have indicated that T cells exert regulatory effects on immune responses by secreting type 1 or 2 cytokines in vivo (10–13). These two types of cells may play different roles in both physiologic and pathologic conditions. Tc1 cells have been shown to induce a stronger delayed-type hypersensitivity reaction than do Tc2 cells in a murine disease model (11). Increases in Th2/Tc2 cell populations have been demonstrated in certain infections and human diseases (4–6). A type 1-to-type 2 cytokine shift may reflect a reduced protective cellular immunity against tumors (26), although both Tc1 and Tc2 subsets are thought to possess a cytolytic function in vitro. The cytolytic potential of Tc1 and Tc2 is proposed to be perforin-mediated. Tc1, but not Tc2, may involve Fas-mediated cytolysis (12).

In the present study, we directly demonstrated that the T cell (both CD4⁰ and CD8⁰ cell) polarity can be driven toward the Th2/Tc2 subset by IL-10 and TGF-β from human cancer cells. In triple-color flow cytometric assays with dual-cytokine intracellular staining, CD3⁺ T cells derived from TILs expressed mainly type 2 cytokine patterns. We further defined the ratios of intracellular cytokine expression in individual CD3⁺ CD4⁰ and CD3⁺ CD8⁰ T cell subsets in TILs and signified the predominant Th2/Tc2 patterns of cytokine expression in the cancer milieu. Using an in vitro coculture model of MLTC, we directly demonstrated that human cancer cells could promote the production of IL-4 and possibly abrogate the production of IFN-γ in cancer-encountered T cells through the synergistic effect of IL-10 and TGF-β.

Our findings link both in vivo data that, for the first time, reveal polarity in TILs and show in vitro for the first time that human cancer cells can drive encountered T cells toward Th2 polarity by cancer-derived mediators. Polarization toward Th2/Tc2 subsets may signify a down-regulation of the cytotoxic potential of TILs.
human malignant tumors, including breast, colon, ovary, cutaneous melanoma, fibrosarcoma, and pancreatic carcinoma (27–35). The mechanisms responsible for the increased expression by tumor cells are not known. It has been suggested that tumor-derived IL-10 may be associated with the down-regulation of anti-tumor immunity by inhibiting the cytotoxicity of CTLs, tumor Ag presentation, and Th1 cell development (27, 28, 35, 36). However, related studies in the literature showed indirect evidences of either elevated IL-4 and IL-10 mRNA, or mixed type 2 cytokine patterns in cancers (28, 37, 38). In the present study, we directly demonstrated predominant in vivo Th2/Tc2 patterns of cytokine expression in subsets of TILs, and stratified that tumor-derived IL-10 promotes a shift toward Th2/Tc2 polarity. The immunosuppressive role of IL-10 has been emphasized as a strategy used by tumors to escape immunosurveillance (39). A recent study by Steinbrink et al. (40), showing that IL-10-treated human dendritic cells can induce anergy in tumor-specific cytotoxic CD8+ T cells and result in failure to lyse tumor cells, further elucidates the down-regulatory role of IL-10 in tumor-mediated immunosuppression.

TGF-β has pleiotropic and potent immunosuppressive effects in the regulation of various physiologic processes. Tumor-derived TGF-β has been shown to down-regulate the generation of tumor-specific cytotoxic lymphocytes (41–43) and the secretion of immunoregulatory cytokines by T cells (42). TGF-β can be a strong costimulator that promotes a shift toward Th2 polarity in rat activated T cells (44). In a tumor-bearing murine model, TGF-β has been shown to shift the Th1/Th2 balance through a direct, IL-10-mediated pathway (45). By secreting IL-10 and TGF-β, tumor cells can affect the activation, proliferation, and differentiation of TILs in a synergistic manner. We have demonstrated in the MLTC model that cancer cells can drive T cell polarity toward the Th2/Tc2 subsets by the synergistic effects of TGF-β and IL-10. The cancer-derived IL-10 and TGF-β may play a synergistic role in the induction of immune privilege in local cancer milieu (46). It is worthy of note that both IL-10 and TGF-β had expressions that progressed from carcinoma in situ to invasive cancer, but were not expressed in normal cervical epithelium of transitional sections (Fig. 4, a–d). The correlated presence of IL-10/TGF-β and Th2/Tc2 polarity of TILs in cancer tissue demonstrates that cancer-derived mediators can be active in modulating T cell functions.

In conclusion, we demonstrated that activated T cells in a human CC milieu predominantly expressed the Th2/Tc2 phenotype. We showed that cancer cells could drive the tumor-encountered T cells toward Th2/Tc2 polarity, which may be attributed to the prominent IL-10 and TGF-β expression in CC cells.

FIGURE 5. Effects of cancer-derived IL-10 and TGF-β on the polarity of cancer-encountered T cells. The levels of IL-4 and IFN-γ in the supernatants were analyzed by ELISA. a, The mean concentration of IFN-γ in the supernatants of MLTC was significantly lower than that of the T-cells-only group after 5 days of coculture (p < 0.01). By adding anti-IL-10 and anti-TGF-β Abs, an increase in the mean concentration IFN-γ in the supernatants of MLTC was observed in day 3 and day 5 cocultures. b, After 5 days of coculture, the concentration of IL-4 in the MLTC group was ~3-fold that in the T-cells-only group (p < 0.01). By addition of anti-IL-10 Ab, the mean concentration of IL-4 in the supernatants of MLTC was reduced in day 3 and day 5 cocultures. Adding both anti-IL-10 and anti-TGF-β Abs to MLTC achieved a maximal reduction of IL-4 in the supernatants, close to the mean concentrations of IL-4 in the supernatants of the T-cells-only group. Data from six independent experiments of cocultures in triplicate are presented as mean ± SD. Various combinations of Abs added to the MLTC cultures (T+C) (●) include anti-TGF-β (●), anti-IL-10 (■), and anti-IL-10 + anti-TGF-β (▲). Activated T cells (T cell-only) were used as controls (○).

and/or render the tumor cells resistant to TIL-mediated cytolyis. Our results confirm that cancer cells may attain immune escape by changing the effector composition of the host immune cells. We further explore the issues of proposed cancer-host immune interactions based on previous in vivo murine models and in vitro cell line results (27–40).

TGF-β and IL-10 are secreted spontaneously by a variety of human malignant tumors, including breast, colon, ovary, cutaneous basal/squamous cancers, metastatic melanoma, fibrosarcoma, and pancreatic carcinoma (27–35). The mechanisms responsible for the increased expression by tumor cells are not known. It has been suggested that tumor-derived IL-10 may be associated with the down-regulation of anti-tumor immunity by inhibiting the cytotoxicity of CTLs, tumor Ag presentation, and Th1 cell develop-

References
1. Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, and B. R. Bloom. 1991. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279.
2. Romagnani, S. 1995. Biology of human Th1 and Th2 cells. J. Clin. Immunol. 15:121.
3. Kelso, A. 1995. Th1 and Th2 subsets: paradigms lost? Immunol. Today 16:374.
4. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
5. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T-cells. Curr. Opin. Immunol. 8:536.
6. Romagnani, S. 1997. The Th1/Th2 paradigm. Immunol. Today 18:263.
7. Seder, R. A., J. L. Boulay, F. Finkelman, S. Barbier, S. Z. Ben-Sasson, G. L. Gros, and W. E. Paul. 1992. CD8+ T cells can be primed in vitro to produce IL-4. J. Immunol. 148:1652.
8. Sad, S., R. Marcotto, and T. R. Mosmann. 1995. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
9. Mosmann, T. R., L. L. and S. Sad. 1997. Functions of CD8 T-cell subsets secreting different cytokine types. Semin. Immunol. 9:87.
10. Cerwenka, A., J. T. Morgan, A. G. Harmsen, and R. W. Dutton. 1998. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189:423.
14. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. *Immunol. Today* 18:493.

15. Miescher, S., M. Stoeck, Q. C. Barra, L. Barrelet, and V. von Fieandt. 1988. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes, impaired response to mitogen-driven stimulation despite T-cell receptor expression. *Int. J. Cancer* 40:599.

16. Hilders, C. G., L. Ras, J. D. van Eendenburg, Y. Nooyen, and G. J. Fleuren. 1994. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. *Int. J. Cancer* 57:805.

17. Ghosh, A. K., and M. Moore. 1992. Tumour-infiltrating lymphocytes in cervical carcinoma. *Eur. J. Cancer* 28A:1910.

18. Bell, M. C., R. P. Edwards, E. E. Partridge, K. Kuykendall, W. Conner, H. Gore, E. Turbat-Herrara, and P. A. Crowley-Nowick. 1995. CD8⁺ T lymphocytes are recruited to neoplastic cervix. *J. Clin. Immunol.* 15:130.

19. Sheu, B. C., R. H. Lin, H. N. Ho, and, S. C. Huang. 1997. Down-regulation of CD25 expression on activated tumor-infiltrating lymphocytes derived from human cervical carcinoma. *Hum. Immunol.* 56:39.

20. Sheu, B. C., S. M. Hsu, H. N. Ho, R. H. Lin, P. L. Torng, and S.C. Huang. 1999. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes correlate with disease progression in human cervical cancer. *Cancer* 86:1537.

21. Cheng, T. Y., J. T. Wu, and R. H. Lin. 1998. Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells. *Int. Immunol.* 10:1397.

22. Heath, W. R., and F. R. Carbone. 1999. Cytotoxic T lymphocyte activation by cross-priming. *Curr. Opin. Immunol.* 11:314.

23. Jung, T., U. Schauer, C. Heusser, C. Neumann, and C. Rieger. 1993. Detection of intracellular cytokines by flow cytometry. *J. Immunol. Methods* 159:197.

24. Assenmacher, M., J. Schmitz, and A. Radbruch. 1994. Flow cytometric determination of cytokines in activated murine T helper lymphocytes: expression of interleukin-10 in interferon-γ and in interleukin-4-expressing cells. *Eur. J. Immunol.* 24:1097.

25. Shu, B. C., S. M. Hsu, H. N. Ho, C. Lien, S. C. Huang, and R. H. Lin. 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. *Cancer Res.* 61:257.

26. Clerici, M., E. Clerici, and G. M. Shearer. 1996. The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. *J. Natl. Cancer Inst.* 88:461.

27. Merogi, A. J., A. J. Marrogi, R. Ramesh, W. R. Robinson, C. D. Fermin, and S. M. Freeman. 1997. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinoma. *Hum. Pathol.* 28:321.

28. Gastl, G. A., J. S. Abrams, D. M. Nanus, R. Oosterkamp, J. Silver, F. Liu, M. Chen, A. P. Albino, and N. H. Bander. 1993. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. *Int. J. Cancer* 55:96.

29. Lüschler, U., L. Filgueira, A. Juretic, M. Zuber, N. J. Lüschler, M. Heberer, and G. C. Spagnoli. 1994. The pattern of cytokine gene expression in freshly excised human uterine melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. *Int. J. Cancer* 57:612.

30. Beauchamp, R. D., H. M. Sheng, C. C. Bascom, D. A. Miller, R. M. Lyons, G. Torre-Amione, and H. L. Moses. 1992. Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-β. *Mucosal Immunol.* 130:2476.

31. Chang, H. L., N. Gillett, J. Figari, A. R. Lopez, M. A. Palladino, and R. Derynck. 1993. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A carcinoma cells. *Cancer Res.* 53:4931.

32. Marrogi, A. J., A. Munshi, A. J. Merogi, Y. Ohadike, A. El-Habashi, O. L. Marrogi, and S. M. Freeman. 1997. Study of tumor-infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. *Int. J. Cancer* 74:492.

33. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. *J. Immunol.* 154:2240.

34. Shi, S. G., E. Plautz, J. C. Krauss, and A. E. Chang. 1997. Tumor immunology. *J. Am. Med. Assoc.* 278:1972.

35. Bellone, G., A. Turletti, E. Artusio, K. Mareschi, A. Carbone, D. Ribaudi, A. Robecchi, G. Emanuelli, and U. Rodeck. 1999. Tumor-associated transforming growth factor-β and interleukin-10 contribute to an immune Th2-like phenotype in pancreatic carcinoma patients. *Am. J. Pathol.* 155:537.

36. Beisert, S., J. Hosoi, S. Grabbe, A. Asahina, and R. D. Granstein. 1995. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. *J. Immunol.* 154:1280.

37. Huang, M., J. Wang, P. Lee, S. Sharma, J. T. Mao, H. Meissner, K. Uyemura, R. Modlin, J. Wollman, and S. M. Dubinett. 1995. Human non-small cell lung cancer cells express a type 2 cytokine pattern. *Cancer Res.* 55:3847.

38. Maurer, M. J., D. M. Neim, C. Castelli, E. Elder, G. Leder, W. J. Storkus, and M. T. Lotze. 1995. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. *Cancer Immunol. Immunother.* 41:111.

39. Salazar-Onfray, F. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. *Med. Oncol.* 16:86.

40. Steinbrink, K., H. Jonuleit, G. Müller, G. Schuler, J. Knop, and A. H. Enk. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific type 1 CD8⁺ T cells resulting in a failure to lyse tumor cells. *Blood* 93:1634.

41. Ruegemer, J. J., S. N. Ho, J. A. Augustine, J. W. Schlager, M. P. Bell, D. J. McKean, and R. T. Abraham. 1990. Regulatory effects of transforming growth factor-β on IL-2- and IL-4-dependent T cell-cycle progression. *J. Immunol.* 144:1756.

42. de Visser, K. E., and W. M. Kast. 1999. Effects of TGF-β on the immune system: implications for cancer immunotherapy. *Leukemia* 13:1188.

43. Torre-Amione, G., R. D. Beauschamp, H. Koeppen, B. H. Park, H. Schreiber, H. L. Moses, and D. A. Rowley. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. *Proc. Natl. Acad. Sci. USA* 87:1486.

44. Schioth, Å., B. Widergren, H. O. Sjögren, and, M. Lindvall. 1998. Transforming growth factor-β1, a strong costimulator of rat T-cell activation promoting a shift towards a Th2-like cytokine profile. *Immunol. Lett.* 67:131.

45. Maeda, H., and A. Shiraishi. 1996. TGF-β and interleukin-10 contribute to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. *J. Immunol.* 156:73.

46. D’Orazio, T. J., and J. Y. Niederkorn. 1998. A novel role for TGF-β and IL-10 in the induction of immune privilege. *J. Immunol.* 160:2089.